These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 5-HT6 receptor antagonists as treatment for age-related cognitive decline. Quiedeville A; Boulouard M; Da Silva Costa-Aze V; Dauphin F; Bouet V; Freret T Rev Neurosci; 2014; 25(3):417-27. PubMed ID: 24622786 [TBL] [Abstract][Full Text] [Related]
5. 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Da Silva Costa-Aze V; Quiedeville A; Boulouard M; Dauphin F Psychopharmacology (Berl); 2012 Jul; 222(1):99-115. PubMed ID: 22367167 [TBL] [Abstract][Full Text] [Related]
6. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Rossé G; Schaffhauser H Curr Top Med Chem; 2010; 10(2):207-21. PubMed ID: 20166958 [TBL] [Abstract][Full Text] [Related]
7. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589 [TBL] [Abstract][Full Text] [Related]
8. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Nikiforuk A Rev Neurosci; 2014; 25(3):367-82. PubMed ID: 24501158 [TBL] [Abstract][Full Text] [Related]
9. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Gravius A; Laszy J; Pietraszek M; Sághy K; Nagel J; Chambon C; Wegener N; Valastro B; Danysz W; Gyertyán I Behav Pharmacol; 2011 Apr; 22(2):122-35. PubMed ID: 21301322 [TBL] [Abstract][Full Text] [Related]
10. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease. Grychowska K; Satała G; Kos T; Partyka A; Colacino E; Chaumont-Dubel S; Bantreil X; Wesołowska A; Pawłowski M; Martinez J; Marin P; Subra G; Bojarski AJ; Lamaty F; Popik P; Zajdel P ACS Chem Neurosci; 2016 Jul; 7(7):972-83. PubMed ID: 27100049 [TBL] [Abstract][Full Text] [Related]
11. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Meltzer HY; Massey BW; Horiguchi M Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753 [TBL] [Abstract][Full Text] [Related]
12. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Brown JW; Rueter LE; Zhang M Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664 [TBL] [Abstract][Full Text] [Related]